CDI, the result of intensive efforts and advances developed by the High-Throughput Biology Center at Johns Hopkins University, is a privately owned research and discovery company in the field of proteomics.
The company was created by scientists for scientists, addressing the critical needs required in order to accelerate research, advance discoveries and translate these discoveries into novel products and services that improve human health.
The company applies its accelerating platforms to internal, collaborative, and client programs.
- Service and technology dissemination provide immediate revenue.
- Internal programs create a pipeline of proprietary biomarker panels and soon-to-be diagnostic and predictive tools in the fields of autoimmunity, oncology, therapeutic outcome, and toxicity prediction.